Evidence mapPaperPMID 41587132Full record

ReviewNeuroendocrinology2026

Is Hypothalamic Dysfunction a Cause of Type II Diabetes Mellitus?

John Karl Young

Abstract readReview
In one paragraph

Review in Neuroendocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

John Karl YoungDepartment of Anatomy, Howard University College of Medicine, Washington, DC, USA, anatomyjohn@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

<p>Background: A number of factors contribute to the development of diabetes mellitus (DM), but until recently, the role of hypothalamic dysfunction in the development of this disorder has not received sufficient attention. Hypothalamic neurons that project to the autonomic nervous system control overall glucose metabolism and insulin sensitivity. These neurons, in turn, are controlled by specialized astrocytes possessing proteins that enable them to function as nutrient sensors for glucose and fatty acids. An aging-related pathological process (that of mitochondrial degeneration) is present in these specific hypothalamic astrocytes. This mitochondrial degeneration can be accelerated by access to a high-fat diet, which also induces hypothalamic resistance to leptin, generalized insulin resistance, and an abnormal glucose homeostasis. An impaired astrocyte-neuron signaling, caused by this pathological mitochondrial degeneration, may underlie an abnormal hypothalamic function that leads to the development of type II diabetes. Pharmacological agents that protect astrocytes from mitochondrial degeneration may have a place in the treatment of type II diabetes. Summary: This article reviews evidence that hypothalamic pathology may make an important contribution to the etiology of type II DM. Key Messages: Abnormalities in hypothalamic astrocytes provoke a disturbed hypothalamic function that contributes to the development of DM. </p>.

Indexed as

AstrocytesDiabetes Mellitus, Type 2Hypothalamic DiseasesHypothalamusAnimalsHumansMitochondriaAstrocytesFatty acid-binding protein 7Gomori-positive astrocytesIronLeptin

Identifiers

PMID41587132
PMCPMC12931931

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.